{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["27(9)"],"submitter":["Boersma LVA"],"funding":["Boston Scientific"],"pubmed_abstract":["<h4>Aims</h4>Clinical studies with protocol-mandated workflow and monitoring have analysed performance of pulsed field ablation (PFA) for treating atrial fibrillation (AF). The FARADISE registry captures global use of the pentaspline PFA catheter in real-world clinical practice with a follow-up of 3 years.<h4>Methods and results</h4>FARADISE is a prospective, non-randomized, multi-national registry (NCT05501873) that enrolled subjects clinically indicated for ablation using the pentaspline PFA catheter per medical judgement and hospital standard-of-care. Procedural characteristics, safety, and clinical effectiveness up to 12-months were collected. In total, 1158 AF patients received PFA across 48 centres in 21 countries (64 ± 11 years, 33% female, 90% de novo, 65% paroxysmal AF). Pulmonary"],"journal":["Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology"],"pagination":["euaf182"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12400809"],"repository":["biostudies-literature"],"pubmed_title":["Real-world experience with the pentaspline pulsed field ablation system: one-year outcomes of the FARADISE registry."],"pmcid":["PMC12400809"],"pubmed_authors":["Willems S","Solimene F","Hussin A","Johnson M","Garcia-Bolao I","Lugenbiel P","Cielen N","Szegedi N","Albrecht EM","Defaye P","Osca J","Sutton BS","Herzet JM","Boersma LVA","Haqqani H","Dello Russo A","Eckardt L","Fiala M","Abbey S","Andrikopoulos G","Ouss A","Vijgen J","Maqueda JR","Efremidis M","Szeplaki G","Luik A","Gandjbakhch E"],"additional_accession":[]},"is_claimable":false,"name":"Real-world experience with the pentaspline pulsed field ablation system: one-year outcomes of the FARADISE registry.","description":"<h4>Aims</h4>Clinical studies with protocol-mandated workflow and monitoring have analysed performance of pulsed field ablation (PFA) for treating atrial fibrillation (AF). The FARADISE registry captures global use of the pentaspline PFA catheter in real-world clinical practice with a follow-up of 3 years.<h4>Methods and results</h4>FARADISE is a prospective, non-randomized, multi-national registry (NCT05501873) that enrolled subjects clinically indicated for ablation using the pentaspline PFA catheter per medical judgement and hospital standard-of-care. Procedural characteristics, safety, and clinical effectiveness up to 12-months were collected. In total, 1158 AF patients received PFA across 48 centres in 21 countries (64 ± 11 years, 33% female, 90% de novo, 65% paroxysmal AF). Pulmonary","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-03T10:15:29.193Z","creation":"2026-04-26T03:12:02.636Z"},"accession":"S-EPMC12400809","cross_references":{"pubmed":["40888735"],"doi":["10.1093/europace/euaf182"]}}